Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Seattle Genetics, Inc. Got Whacked Today

By Brian Orelli, PhD – Jun 26, 2017 at 1:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sometimes good news isn't good enough.

What happened

Seattle Genetics (SGEN 0.64%) stock is down 8.7% as of 1:02 p.m. after the company announced positive phase 3 data from its ECHELON-1 trial testing Adcetris as a first-line treatment for Hodgkin lymphoma.

So what

You read that right: Shares are down on positive clinical trial results. Unfortunately, in biotech, sometimes it's the magnitude of the win that counts.

Seattle Genetics' ECHELON-1 trial tested Adcetris, which is already approved as a treatment for Hodgkin lymphoma after stem cell transplantation, in combination with older chemotherapy drugs -- adriamycin, vinblastine, dacarbazine (AVD) -- compared to the standard of care that includes those three drugs plus bleomycin (AVBD). The group that got Adcetris+AVD had a 23% reduction in the risk of modified progression-free survival -- defined as progression, death, or patients getting an additional anticancer therapy because they didn't have a complete response -- compared to the patients that got AVBD. Looking specifically two years after the start of treatment, 82.1% of patients that got Adcetris+AVD hadn't triggered the modified progression-free survival criteria compared to 77.2% in the control arm.

Doctor talking to patient

Image source: Getty Images.

While there's a clear benefit from Adcetris+AVD over AVBD, the benefit isn't particularly large, with just an additional 5% of patients doing better after two years. That might cause pushback from insurers, as Adcetris is significantly more expensive than bleomycin, which is available as a generic. Keep in mind, though, that bleomycin is quite toxic and treating the side effects has costs associated with it, which insurers should take into account in their cost-benefit analysis.

Now what

Investors will have to wait for until December at the American Society of Hematology meeting to see the full results from ECHELON-1, but the top-line data looks good enough for Seattle Genetics to be able to gain regulatory approval in the U.S. and elsewhere by its partner Takeda. The bigger question now is how much additional drug the duo can sell, but we won't know the answer to that until Adcetris starts getting expanded regulatory approvals in a year or so.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
$137.70 (0.64%) $0.87

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.